 |
 |
 |
|
Pharmacokinetics and Safety of Boosted-Elvitegravir in Subjects with Hepatic Impairment
|
|
|
Reported by Jules Levin
13th HIV Clinical Workshop Apr 16-18 2012 Barcelona Spain
S Ramanathan, M Rhee, G Shen, J Custodio, and BP Kearney
Gilead Sciences, Inc., Foster City, CA, USA






|
|
|
 |
 |
|
|